Bio-Fd&C바이오에프디엔씨

Bio-Fd&C is highly profitable on filed numbers, but its share price is still far below its 52-week high after a steep one-year fall.

The company makes plant-cell-derived ingredients for cosmetics, health foods and pharmaceuticals. On trailing figures to H1 2026 it reports revenue of ₩19.5B...

What stands out

• Trailing revenue to H1 2026 is about ₩19.5B with operating income of about ₩6.1B, an operating margin of 31.2%.
• Full-year 2025 revenue grew 19.4% to about ₩19.2B, while 2024 growth was only 3%.
• Trailing cash of about ₩12.4B against borrowings of about ₩1.1B; liabilities are 4.7% of equity.
• The shares closed at ₩9,920, down 40.8% over one year but up 26.4% over three months; the 52-week range is ₩6,330 to ₩17,730.
• The DCF fair value model gives a base of ₩16,524, with a bear case of ₩13,372 and a bull case of ₩21,594; this is a model output, not a forecast.
• Foreign ownership fell from 11.6% to 10.7% over the last 60 days, and foreign investors were net sellers over the last 20 days.

What to watch

• The Q3 quarterly report and any updates to the 2026 results, which are not yet in the data.
• Continued 5%+ holding reports, including the amended filing from October 6, 2026; the reasons are not stated in the data.
• Commercialisation of plant-cell-based pharmaceuticals, which the company describes only as a medium to long-term plan; the data names no timeline.